B Maharaj1, T N Gengiah1, N Yende-Zuma1, S Gengiah1, A Naidoo1, K Naidoo2. 1. Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban. 2. Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, Medical Research Council-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa.
Abstract
SETTING: Urban clinical research site in Durban, South Africa. OBJECTIVE: To describe outcomes associated with the implementation of isoniazid preventive therapy (IPT) in a cohort of tuberculosis (TB) treatment-experienced human immunodeficiency virus (HIV) infected patients on antiretroviral therapy (ART). DESIGN: We conducted a secondary analysis of data collected between October 2009 and October 2013 from patients enrolled in a prospective cohort study conducted in Durban, South Africa. RESULTS: Of the 402 patients enrolled in the parent study, 344 (85.6%) were eligible for IPT, 212 of whom (61.6%) initiated IPT. Of those who initiated IPT, 184 (86.8%) completed the 6-month course, while 24 (11.3%) permanently discontinued IPT, 3.8% of whom due to side effects. More women than men initiated IPT (n = 130, 61.3% vs. n = 82, 38.7%, P = 0.001). Overall median adherence to IPT was 97.6% (interquartile range 94.2-99.4). There were 22 cases of incident TB in this cohort: 13 occurred before IPT and 9 after (incidence rate ratio 0.67, 95%CI 0.29-1.58, P = 0.362). CONCLUSIONS: IPT implementation among ART and TB treatment-experienced patients was well tolerated, with good completion rates and fewer TB cases diagnosed after IPT.
SETTING: Urban clinical research site in Durban, South Africa. OBJECTIVE: To describe outcomes associated with the implementation of isoniazid preventive therapy (IPT) in a cohort of tuberculosis (TB) treatment-experienced human immunodeficiency virus (HIV) infectedpatients on antiretroviral therapy (ART). DESIGN: We conducted a secondary analysis of data collected between October 2009 and October 2013 from patients enrolled in a prospective cohort study conducted in Durban, South Africa. RESULTS: Of the 402 patients enrolled in the parent study, 344 (85.6%) were eligible for IPT, 212 of whom (61.6%) initiated IPT. Of those who initiated IPT, 184 (86.8%) completed the 6-month course, while 24 (11.3%) permanently discontinued IPT, 3.8% of whom due to side effects. More women than men initiated IPT (n = 130, 61.3% vs. n = 82, 38.7%, P = 0.001). Overall median adherence to IPT was 97.6% (interquartile range 94.2-99.4). There were 22 cases of incident TB in this cohort: 13 occurred before IPT and 9 after (incidence rate ratio 0.67, 95%CI 0.29-1.58, P = 0.362). CONCLUSIONS:IPT implementation among ART and TB treatment-experienced patients was well tolerated, with good completion rates and fewer TB cases diagnosed after IPT.
Authors: C Kabali; C F von Reyn; D R Brooks; R Waddell; L Mtei; M Bakari; M Matee; K Pallangyo; R D Arbeit; C R Horsburgh Journal: Int J Tuberc Lung Dis Date: 2011-11 Impact factor: 2.373
Authors: Neil A Martinson; Grace L Barnes; Lawrence H Moulton; Reginah Msandiwa; Harry Hausler; Malathi Ram; James A McIntyre; Glenda E Gray; Richard E Chaisson Journal: N Engl J Med Date: 2011-07-07 Impact factor: 91.245
Authors: Alison D Grant; Salome Charalambous; Katherine L Fielding; John H Day; Elizabeth L Corbett; Richard E Chaisson; Kevin M De Cock; Richard J Hayes; Gavin J Churchyard Journal: JAMA Date: 2005-06-08 Impact factor: 56.272
Authors: Gavin J Churchyard; Katherine Fielding; Salome Charalambous; John H Day; Elizabeth L Corbett; Richard J Hayes; Richard E Chaisson; Kevin M De Cock; Badara Samb; Alison D Grant Journal: AIDS Date: 2003-09-26 Impact factor: 4.177
Authors: Bongani M Mayosi; Joy E Lawn; Ashley van Niekerk; Debbie Bradshaw; Salim S Abdool Karim; Hoosen M Coovadia Journal: Lancet Date: 2012-11-30 Impact factor: 79.321
Authors: Kesetebirhan Delele Yirdaw; Degu Jerene; Zewdu Gashu; M E Edginton; Ajay M V Kumar; Yohannes Letamo; Beniam Feleke; Alula M Teklu; Solomon Zewdu; Bill Weiss; Andrea Ruff Journal: PLoS One Date: 2014-08-08 Impact factor: 3.240
Authors: Masanja Robert; Jim Todd; Bernard J Ngowi; Sia E Msuya; Angella Ramadhani; Veryhel Sambu; Isaya Jerry; Martin R Mujuni; Michael J Mahande; James S Ngocho; Werner Maokola Journal: BMC Infect Dis Date: 2020-04-10 Impact factor: 3.090
Authors: Clay Roscoe; Chris Lockhart; Michael de Klerk; Andrew Baughman; Simon Agolory; Michael Gawanab; Heather Menzies; Anna Jonas; Natanael Salomo; Negussie Taffa; David Lowrance; Katherine Robsky; Deanna Tollefson; Eric Pevzner; Ndapewa Hamunime; Farai Mavhunga; Helena Mungunda Journal: BMC Public Health Date: 2020-12-01 Impact factor: 3.295
Authors: Muthoni Karanja; Leonard Kingwara; Philip Owiti; Elvis Kirui; Faith Ngari; Richard Kiplimo; Maurice Maina; Enos Masini; Elizabeth Onyango; Catherine Ngugi Journal: PLoS One Date: 2020-12-02 Impact factor: 3.240
Authors: Michael Melgar; Ray W Shiraishi; Clifford Tende; Sydney Mwanza; Joyce Mulenga; Shepherd Khondowe; David Mwakazanga; Kelvin Kapungu; Mathias Tembo; Amos Nota; Patrick Lungu; Brittany Moore; Laura J Podewils Journal: BMC Public Health Date: 2021-05-04 Impact factor: 3.295
Authors: Stephanie Fischinger; Deniz Cizmeci; Sally Shin; Leela Davies; Patricia S Grace; Aida Sivro; Nonhlanhla Yende-Zuma; Hendrik Streeck; Sarah M Fortune; Douglas A Lauffenburger; Kogieleum Naidoo; Galit Alter Journal: Front Immunol Date: 2021-09-22 Impact factor: 7.561